Epoprostenol Sodium
featured

    WARNING: This product is for research use only, not for human or veterinary use.

Hodoodo CAT#: H317779

CAS#: 61849-14-7

Description: Epoprostenol Sodium is a potent vasodilator and antiplatelet substance with a very short physiologic half-life. The sodium salt is used primarily for the treatment of pulmonary hypertension. Epoprostenol sodium inhibits platelet aggregation. It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue.

Chemical Structure

img
Epoprostenol Sodium
CAS# 61849-14-7
Instruction

Theoretical Analysis

Hodoodo Cat#: H317779
Name: Epoprostenol Sodium
CAS#: 61849-14-7
Chemical Formula: C20H31NaO5
Exact Mass: 0.00
Molecular Weight: 374.450
Elemental Analysis: C, 64.15; H, 8.34; Na, 6.14; O, 21.36

Price and Availability

Size Price Availability Quantity
1mg USD 245 2 weeks
5mg USD 600 2 weeks
10mg USD 950 2 weeks
25mg USD 1900 2 weeks
Bulk inquiry

Synonym: Epoprostenol Sodium; Flolan; Prostaglandin I2; UNII-4K04IQ1OF4; Prostacyclin; EINECS 263-273-7; Flolan; PGI2; PGX; Prostacyclin; Prostaglandin I(2); Prostaglandin I2;

IUPAC/Chemical Name: sodium;(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoate

InChi Key: LMHIPJMTZHDKEW-XQYLJSSYSA-M

InChi Code: InChI=1S/C20H32O5.Na/c1-2-3-4-7-14(21)10-11-16-17-12-15(8-5-6-9-20(23)24)25-19(17)13-18(16)22;/h8,10-11,14,16-19,21-22H,2-7,9,12-13H2,1H3,(H,23,24);/q;+1/p-1/b11-10+,15-8-;/t14-,16+,17+,18+,19-;/m0./s1

SMILES Code: CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1C/C(=C/CCCC(=O)[O-])/O2)O)O.[Na+]

Appearance: Solid powder

Purity: >95% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 374.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Saito Y, Nakamura K, Akagi S, Sarashina T, Ejiri K, Miura A, Ogawa A,
Matsubara H, Ito H. Epoprostenol sodium for treatment of pulmonary arterial
hypertension. Vasc Health Risk Manag. 2015 May 14;11:265-70. doi:
10.2147/VHRM.S50368. eCollection 2015. Review. PubMed PMID: 25999730; PubMed
Central PMCID: PMC4437604.


2: Chin KM, Badesch DB, Robbins IM, Tapson VF, Palevsky HI, Kim NH, Kawut SM,
Frost A, Benton WW, Lemarie JC, Bodin F, Rubin LJ, McLaughlin V. Two formulations
of epoprostenol sodium in the treatment of pulmonary arterial hypertension:
EPITOME-1 (epoprostenol for injection in pulmonary arterial hypertension), a
phase IV, open-label, randomized study. Am Heart J. 2014 Feb;167(2):218-225.e1.
doi: 10.1016/j.ahj.2013.08.008. Epub 2013 Oct 16. PubMed PMID: 24439983.


3: Tamura Y, Ono T, Fukuda K, Satoh T, Sasayama S. Evaluation of a new
formulation of epoprostenol sodium in Japanese patients with pulmonary arterial
hypertension (EPITOME4). Adv Ther. 2013 May;30(5):459-71. doi:
10.1007/s12325-013-0029-0. Epub 2013 May 8. Erratum in: Adv Ther. 2013
May;30(5):554-5. PubMed PMID: 23653230; PubMed Central PMCID: PMC3680653.


4: Nicolas LB, Gutierrez MM, Dingemanse J. Comparative pharmacokinetic,
pharmacodynamic, safety, and tolerability profiles of 3 different formulations of
epoprostenol sodium for injection in healthy men. Clin Ther. 2013
Apr;35(4):440-9. doi: 10.1016/j.clinthera.2013.02.013. Epub 2013 Mar 15. PubMed
PMID: 23498778.


5: Lambert O, Bandilla D. Stability and preservation of a new formulation of
epoprostenol sodium for treatment of pulmonary arterial hypertension. Drug Des
Devel Ther. 2012;6:235-44. doi: 10.2147/DDDT.S31628. Epub 2012 Sep 17. PubMed
PMID: 23049244; PubMed Central PMCID: PMC3459691.


6: Lambert O, Bandilla D, Iyer R, Witchey-Lakshmanan L, Palepu N. Stability and
microbiological properties of a new formulation of epoprostenol sodium when
reconstituted and diluted. Drug Des Devel Ther. 2012;6:61-70. doi:
10.2147/DDDT.S29916. Epub 2012 Mar 28. PubMed PMID: 22563237; PubMed Central
PMCID: PMC3340107.


7: Carlton LD, Schmith VD, Brouwer KL. Intravenous epoprostenol sodium does not
increase hepatic microsomal enzyme activity in rats. Prostaglandins. 1995
Nov-Dec;50(5-6):341-7. PubMed PMID: 8838243.


8: Caruana RJ, Smith MC, Clyne D, Crow JW, Zinn JM, Diehl JH. Controlled study of
heparin versus epoprostenol sodium (prostacyclin) as the sole anticoagulant for
chronic hemodialysis. Blood Purif. 1991;9(5-6):296-304. PubMed PMID: 1819317.


9: Reele SB, Miller OV, Spillers C, Gorman RR. The effects of continuous
infusions of prostacyclin-Na (epoprostenol-sodium) on platelet counts,
ADP-induced aggregation, and cyclic AMP levels in normal volunteers.
Prostaglandins. 1983 Aug;26(2):287-302. PubMed PMID: 6316420.


10: Yamamoto K, Sakata R, Iguro Y, Ueno T, Ueno M, Ueno T. Intraoperative
infusion of epoprostenol sodium for patients with heparin-induced
thrombocytopenia undergoing cardiac surgery. Jpn J Thorac Cardiovasc Surg. 2006
Aug;54(8):348-50. PubMed PMID: 16972642.


11: von Heymann C, Hagemeyer E, Kastrup M, Ziemer S, Proquitté H, Konertz WF,
Spies C. Heparin-induced thrombocytopenia type II in an infant with a congenital
heart defect--anticoagulation during cardiopulmonary bypass with epoprostenol
sodium and heparin. Pediatr Crit Care Med. 2006 Jul;7(4):383-5. PubMed PMID:
16738494.


12: Kawabe M, Hagiwara A, Yoshino H, Miyashita K, Nakanishi T, Sano M, Tamano S,
Okamoto K, Miura K, Tokado H. Epoprostenol sodium, a prostaglandin I2, lacks
tumor promoting effects in a medium-term liver carcinogenesis bioassay in rats.
Cancer Lett. 2001 Jan 26;162(2):141-7. PubMed PMID: 11146218.


13: Castro PF, Bourge RC, McGiffin DC, Benza RL, Fan P, Pinkard NB, McGoon MD.
Intrapulmonary shunting in primary pulmonary hypertension: an observation in two
patients treated with epoprostenol sodium. Chest. 1998 Jul;114(1):334-6. PubMed
PMID: 9674493.


14: Kiernan FJ, Kluger J, Regnier JC, Rutkowski M, Fieldman A. Epoprostenol
sodium (prostacyclin) infusion in acute myocardial infarction. Br Heart J. 1986
Nov;56(5):428-32. PubMed PMID: 3539163; PubMed Central PMCID: PMC1236888.

img

RUN26658

 5g / USD 270